Hospital-acquired pneumonia in Japan may have a better mortality profile than HAP in the United States: a retrospective study

2012 ◽  
Vol 18 (5) ◽  
pp. 734-740 ◽  
Author(s):  
Kentaro Iwata ◽  
Wataru Igarashi ◽  
Yuichiro Oba ◽  
Goh Ohji ◽  
Midori Honjo ◽  
...  
Keyword(s):  
United States ◽  
Retrospective Study ◽  
The United States ◽  
Hospital Acquired Pneumonia ◽  
Hospital Acquired

scholarly journals In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States

2008 ◽  
Vol 52 (12) ◽  
pp. 4388-4399 ◽  
Author(s):  
Chris M. Pillar ◽  
Mohana K. Torres ◽  
Nina P. Brown ◽  
Dineshchandra Shah ◽  
Daniel F. Sahm
Keyword(s):  
The United States ◽  
Clinical Isolates ◽  
Gram Negative Bacteria ◽  
Ventilator Associated Pneumonia ◽  
Coagulase Negative Staphylococci ◽  
Hospital Acquired Pneumonia ◽  
Abdominal Infections ◽  
Hospital Acquired ◽  
Gram Positive Cocci

ABSTRACT Doripenem, a 1β-methylcarbapenem, is a broad-spectrum antibiotic approved for the treatment of complicated urinary tract and complicated intra-abdominal infections. An indication for hospital-acquired pneumonia including ventilator-associated pneumonia is pending. The current study examined the activity of doripenem against recent clinical isolates for the purposes of its ongoing clinical development and future longitudinal analysis. Doripenem and comparators were tested against 12,581 U.S. clinical isolates collected between 2005 and 2006 including isolates of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pneumoniae, Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. MICs (μg/ml) were established by broth microdilution. By MIC90, doripenem was comparable to imipenem and meropenem in activity against S. aureus (methicillin susceptible, 0.06; resistant, 8) and S. pneumoniae (penicillin susceptible, ≤0.015; resistant, 1). Against ceftazidime-susceptible Enterobacteriaceae, the MIC90 of doripenem (0.12) was comparable to that of meropenem (0.12) and superior to that of imipenem (2), though susceptibility of isolates exceeded 99% for all evaluated carbapenems. The activity of doripenem was not notably altered against ceftazidime-nonsusceptible or extended-spectrum β-lactamase screen-positive Enterobacteriaceae. Doripenem was the most potent carbapenem tested against P. aeruginosa (MIC90/% susceptibility [%S]: ceftazidime susceptible = 2/92%S, nonsusceptible = 16/61%S; imipenem susceptible = 1/98.5%S, nonsusceptible = 8/56%S). Against imipenem-susceptible Acinetobacter spp., doripenem (MIC90 = 2, 89.1%S) was twice as active by MIC90 as were imipenem and meropenem. Overall, doripenem potency was comparable to those of meropenem and imipenem against gram-positive cocci and doripenem was equal or superior in activity to meropenem and imipenem against Enterobacteriaceae, including β-lactam-nonsusceptible isolates. Doripenem was the most active carbapenem tested against P. aeruginosa regardless of β-lactam resistance.

Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets

2016 ◽  
Vol 22 (6) ◽  
pp. 723-732u ◽  
Author(s):  
Elizabeth MacLean ◽  
Laura Cisar ◽  
Kimberly Mehle ◽  
Daria Eremina ◽  
Jane M. Quigley
Keyword(s):  
United States ◽  
Retrospective Study ◽  
Real World ◽  
The United States

scholarly journals Identification and Management of Sepsis in the Interventional Radiology Patient

2017 ◽  
Vol 1 ◽  
pp. 3
Author(s):  
Jacqueline Murtha ◽  
Vinit Khanna ◽  
Talia Sasson ◽  
Devang Butani
Keyword(s):  
United States ◽  
Health Care ◽  
Septic Shock ◽  
Interventional Radiology ◽  
Hospital Setting ◽  
The United States ◽  
Clinical Aspects ◽  
Inhospital Mortality ◽  
United States Population ◽  
Hospital Acquired

Sepsis is frequently encountered in the hospital setting and can be community-acquired, health-care-associated, or hospital-acquired. The annual incidence of sepsis in the United States population ranges from 300 to 1031 per 100,000 and is increasing by 13% annually. There is an associated inhospital mortality of 10% for sepsis and >40% for septic shock. Interventional radiology is frequently called on to treat patients with sepsis, and in rarer circumstances, interventional radiologists themselves may cause sepsis. Thus, it is essential for interventional radiologists to be able to identify and manage septic patients to reduce sepsis-related morbidity and mortality. The purpose of this paper is to outline procedures most likely to cause sepsis and delineate important clinical aspects of identifying and managing septic patients.

scholarly journals Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Chih-Han Juan ◽  
Shih-Yu Fang ◽  
Chia-Hsin Chou ◽  
Tsung-Ying Tsai ◽  
Yi-Tsung Lin
Keyword(s):  
Retrospective Study ◽  
Klebsiella Pneumoniae ◽  
Clinical Characteristics ◽  
Community Acquired Pneumonia ◽  
Drug Resistant ◽  
Hospital Acquired Pneumonia ◽  
Resistant Strains ◽  
Healthcare Associated ◽  
Drug Resistant Strains ◽  
Hospital Acquired

Abstract Background We aimed to compare the clinical characteristics of patients with community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), and hospital-acquired pneumonia (HAP) caused by Klebsiella pneumoniae and analyze the antimicrobial resistance and proportion of hypervirluent strains of the microbial isolates. Methods We conducted a retrospective study on patients with pneumonia caused by K. pneumoniae at the Taipei Veterans General Hospital in Taiwan between January 2014 and December 2016. To analyze the clinical characteristics of these patients, data was extracted from their medical records. K. pneumoniae strains were subjected to antimicrobial susceptibility testing, capsular genotyping and detection of the rmpA and rmpA2 genes to identify hypervirulent strains. Results We identified 276 patients with pneumonia caused by K. pneumoniae, of which 68 (24.6%), 74 (26.8%), and 134 (48.6%) presented with CAP, HCAP, and HAP, respectively. The 28-day mortality was highest in the HAP group (39.6%), followed by the HCAP (29.7%) and CAP (27.9%) groups. The HAP group also featured the highest proportion of multi-drug resistant strains (49.3%), followed by the HCAP (36.5%) and CAP groups (10.3%), while the CAP group had the highest proportion of hypervirulent strains (79.4%), followed by the HCAP (55.4%) and HAP groups (41.0%). Conclusion Pneumonia caused by K. pneumoniae was associated with a high mortality. Importantly, multi-drug resistant strains were also detected in patients with CAP. Hypervirulent strains were prevalent in all 3 groups of pneumonia patients, even in those with HAP.

Sign in / Sign up

Export Citation Format

Share Document